Clopidogrel and Seizure Risk

Mechanism of Action and Primary Side Effects

Clopidogrel is an oral thienopyridine prodrug that irreversibly inhibits the adenosine diphosphate receptor on platelets, resulting in reduced platelet aggregation through a different mechanism than aspirin 1
The most common adverse effects of clopidogrel include bleeding complications, gastrointestinal issues, rash, and pruritus 2, 3
Thrombotic Thrombocytopenic Purpura (TTP) is a rare but serious adverse effect that can occur after initiating clopidogrel therapy, typically within the first 2 weeks of treatment 2, 4

Major clinical guidelines and trials of clopidogrel do not list seizures as a known adverse effect 1, 2, 3

Documented hematologic adverse effects of clopidogrel include Thrombotic thrombocytopenia purpura 2 and Neutropenia 3

Monitoring should focus on signs of bleeding, which is the most common adverse effect of clopidogrel therapy 5
The HAS-BLED score can be used to assess bleeding risk in patients on antithrombotic therapy including clopidogrel 5

When prescribing clopidogrel, clinicians should be vigilant about bleeding risk but do not need to consider seizure risk as a factor in decision-making 2, 4